Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma.
Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, Luca Burgio S, Berardi R, Muzzonigro G, Cortesi E, Amadori D, Cascinu S. Santoni M, et al. Among authors: cortesi e. Br J Cancer. 2013 Oct 1;109(7):1755-9. doi: 10.1038/bjc.2013.522. Epub 2013 Sep 5. Br J Cancer. 2013. PMID: 24008663 Free PMC article.
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello GP, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco AR. De Placido S, et al. Among authors: cortesi e. Br J Cancer. 2005 Oct 17;93(8):896-904. doi: 10.1038/sj.bjc.6602800. Br J Cancer. 2005. PMID: 16222322 Free PMC article. Clinical Trial.
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I; Italian Group for the Study of Digestive Tract Cancer; Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A. Cascinu S, et al. Among authors: cortesi e. J Natl Cancer Inst. 2007 Apr 18;99(8):601-7. doi: 10.1093/jnci/djk131. J Natl Cancer Inst. 2007. PMID: 17440161 Clinical Trial.
Neo-adjuvant and adjuvant chemotherapy in bladder cancer.
D'Auria G, Ciprotti M, Conte D, Iacovelli R, Palazzo A, Pellegrino A, Cortesi E. D'Auria G, et al. Among authors: cortesi e. Ann Oncol. 2007 Jun;18 Suppl 6:vi162-3. doi: 10.1093/annonc/mdm248. Ann Oncol. 2007. PMID: 17591814 Free article. Review. No abstract available.
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S. Sartore-Bianchi A, et al. Among authors: cortesi e. J Clin Oncol. 2007 Aug 1;25(22):3238-45. doi: 10.1200/JCO.2007.11.5956. J Clin Oncol. 2007. PMID: 17664472 Clinical Trial.
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A. Loupakis F, et al. Among authors: cortesi e. Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. doi: 10.1007/s00280-009-1196-1. Epub 2010 Mar 17. Cancer Chemother Pharmacol. 2010. PMID: 20237927 Clinical Trial.
Past, present and future of targeted therapy in solid tumors.
Palazzo A, Iacovelli R, Cortesi E. Palazzo A, et al. Among authors: cortesi e. Curr Cancer Drug Targets. 2010 Aug;10(5):433-61. doi: 10.2174/156800910791517145. Curr Cancer Drug Targets. 2010. PMID: 20384576 Review.
Neoadjuvant targeted therapy in renal cell carcinoma.
Iacovelli R, Raimondi C, Palazzo A, Cortesi E, Procopio G. Iacovelli R, et al. Among authors: cortesi e. Nat Rev Urol. 2010 Jul;7(7):doi:10.1038/nrurol.2010.2-c1; author reply doi:10.1038/nrurol.2010.2-c2. doi: 10.1038/nrurol.2010.2-c1. Nat Rev Urol. 2010. PMID: 20665981 No abstract available.
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A. Fornaro L, et al. Among authors: cortesi e. Clin Colorectal Cancer. 2012 Mar;11(1):71-6. doi: 10.1016/j.clcc.2011.06.013. Epub 2011 Sep 8. Clin Colorectal Cancer. 2012. PMID: 21903485
290 results